NCT05940480Active, not recruiting
TCM Daoyin Therapy in Individuals At-risk for COPD
TCM Daoyin Therapy in Early Chronic Obstructive Pulmonary Disease: A Pilot Study
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease. The aim of prospective randomized study is to evaluate the effects of TCM Daoyin training on Individuals at-risk for COPD.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 4 Jul 2023
- Start date
- 3 Jan 2023
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Shanghai University of Traditional Chinese Medicine
- Diseases
- COPD
- NCT number
- NCT05940480
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 3 Jan 2023 to the primary completion date, 30 Jun 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subject with respiratory infectious disease (e.g., tuberculosis, influenza, etc.) within 1 month.
- Subject with serious current unstable physical illness and mental illness.
- Subject with definite clinical diagnosis of Alzheimer's disease, or severe cognitive impairment.
Other
- Subject with acute exacerbation of COPD.
- Subject is pregnant or lactating women.
Who the study is looking for
- Subject at-risk for COPD (Chronic obstructive pulmonary disease screening questionnaire (COPD-SQ) score≥16; and pre-bronchodilator FEV1/FVC ≥ 0.70, or pre-bronchodilator FEV1/FVC\<0.70 but post-bronchodilator FEV1/FVC ≥ 0.70).
- Aged 40 to 75, male or female.
- Subject has a clear mind and the ability to lead an independent life.
- Subject agrees to perform a blood-test.
- Subject agrees to participate in this study and sign to the informed consent.
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Qigong Research Institute Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Changzheng Community Health Service Center of Putuo District, Shanghai Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.